Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: A randomised, prospective, controlled multi-institutional trial

BJU International

Volumn 112, Issue 7, 2013, Pages 925-929

  Eggener, Scott E ^a   Large, Michael C ^a   Gerber, Glenn S ^a   Pettus, Joseph ^d   Yossepowitch, Ofer ^f   Smith, Norm D ^a   Kundu, Shilajit ^b   Kunnavakkam, Rangesh ^c   Zorn, Kevin ^g   Raman, Jay D ^e  

^a Mail Code 6038 ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Urologic Clinics of North Alabama   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

antibiotics; ciprofloxacin; prostate cancer; prostatitis; PSA

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; PROSTATE SPECIFIC ANTIGEN;

ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; ASYMPTOMATIC DISEASE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBIOTICS; CIPROFLOXACIN; PROSTATE CANCER; PROSTATITIS; PSA;

AGED; ANTI-BACTERIAL AGENTS; BIOPSY; CIPROFLOXACIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN;

EID: 84886095162     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12241     Document Type: Article

References (21)

1. Bostwick DG, Meiers I,. Prostate biopsy and optimization of cancer yield. Eur Urol 2006; 49: 415-417
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236
3. Lin YK, Gettle L, Raman JD,. Variable prostate-specific antigen management patterns by nonurologist providers at a tertiary care medical center. Urology 2011; 78: 244-248
4. Owens RC Jr, Ambrose PG,. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144-157
5. Kahlmeter G, Menday P, Cars O,. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003; 52: 1005-1010
6. Akduman B, Akduman D, Tokgöz H, et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011; 78: 250-255
7. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952-955
8. Erol H, Beder N, Calişkan T, et al. Can the effect of antibiotherapy and anti- inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? Urol Int 2006; 76: 20-26
9. Kaygisiz O, Uǧurlu O, Koşan M, et al. Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml. Prostate Cancer Prostatic Dis 2006; 9: 235-238
10. Serretta V, Catanese A, Daricello G, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis 2008; 11: 148-152
11. Shtricker A, Shefi S, Ringel A, et al. PSA levels of 4.0-10 ng/mL and negative digital rectal examination. Antibiotic therapy versus immediate prostate biopsy. Int Braz J Urol 2009; 35: 551-558
12. Baltaci S, Süer E, Haliloǧlu AH, et al. Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. J Urol 2009; 181: 128-132
13. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-2700
14. Matts JP, Lachin JM,. Properties of permuted-block randomization in clinical trials. Control Clin Trials 1988; 9: 327-344
15. Dalton DL,. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465
16. Ornstein DK, Smith DS, Rao GS, et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157: 2179-2182
17. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413
18. Schaeffer AJ, Wu SC, Tennenberg AM, et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 2005; 174: 161-164
19. Stopiglia RM, Ferreira U, Silva MM Jr, et al. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol 2010; 183: 940-944
20. Kyung YS, Lee HC, Kim HJ,. Changes in serum prostate-specific antigen after treatment with antibiotics in patients with lower urinary tract symptoms/benign prostatic hyperplasia with prostatitis. Int Neurourol J 2010; 14: 100-104
21. Loeb S, Gashti SN, Catalona WJ,. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol 2009; 27: 64-66